GI & Endoscopy

Here are seven updates from gastroenterology companies and practices from the past week:

Exact Sciences posted fourth-quarter 2019 revenues of $295.6 million and full-year revenues of $876.3 million.   

Dr. Reddy's Laboratories will acquire select divisions of Wockhardt Limited's branded generics business in India, Nepal, Sri Lanka, Bhutan and Maldives.

Statistics show that about one in three of U.S. adults ages 50-75 are not getting screened for colorectal cancer as recommended.

Mercy Health-Lorain (Ohio) Hospital opened a gastroenterology center in a vacant space in the facility, The Chronicle reports.

  Five must read articles for gastronterologists this week:

Exact Sciences' multitarget stool DNA test, Cologuard, is divisive. Touting 92 percent sensitivity and 87 percent specificity rates for detecting all stages of colorectal cancer, the test is heavily marketed and has seen significant growth recently. 

The U.S. Multi-Society Task Force on Colorectal Cancer updated its 2012 recommendations for postcolonoscopy follow-up with or without polypectomy, according to an article in Gastroenterology Consultant.

Here are four GI leaders who have joined new organizations in the past year:

Three gastroenterologists making headlines this week: